Best of ASCO - 2014 Annual Meeting

 

Welcome

Circulating Biomarkers

Tumor Biology

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A priori filtering of post-operative (post-op) circulating tumor DNA (ctDNA) to predict recurrence in post-metastasectomy colorectal cancer patients (CRC pts) without knowledge of tumor genotype.

Michael J. Overman

12044

An enhanced next-generation sequencing liquid biopsy assay for simultaneous detection of somatic variants, microsatellite instability and viral DNA.

Yukti Choudhury

e24107

Analysis of single circulating tumor cells (CTCs) to identify resistance mutations to ALK-inhibitors in both ALK-gene and bypass oncogenic pathways.

Emma Pailler

12038

Application of capture-based sequencing in predicting pathologic response to neoadjuvant therapy in HER2-positive breast cancer.

Fei Ma

e24073

Applications of liquid biopsies as prognostic markers in patients (pts) with advanced ovarian cancer (AOC) on metronomic cyclophosphamide (MCy) with or without nintedanib (N) (Trans METRO-BIBF).

Marcia Hall

e24065

Bromodomain-containing protein 7 as tumour suppressor and prognostic biomarker in breast cancer.

Cristiana Lo Nigro

e24047

Cell free tumor DNA ( CfTDNA) in cervical carcinoma as diagnostic and prognostic marker: Pilot study.

H B Govardhan

e24100

Cell-free circulating tumor DNA somatic alteration burden and its impact on survival in metastatic cancer.

Seyed Saeed Pairawan

12022

Cell-free circulating tumour DNA (ctDNA) in the management of patients (pts) with non-biopsiable (Bx) advanced non-small cell lung cancer (NSCLC).

MArina Kushnir

e24044

Circulating free plasma tumor DNA in patients with advanced gastric cancer receiving systemic chemotherapy.

Savia Raquel Costa Normando

e24067

Circulating PD-L1+ exosomes as potential prognostic and predictive biomarkers in pulmonary lymphoepithelioma-like carcinoma.

Mian Xie

e24081

Circulating tumor cells enumeration (CTCs) and circulating tumor DNA (ctDNA): Clinical and molecular features of “rapidly progressing” stage IV disease (Stage IVprog).

Lorenzo Gerratana

12040

Circulating tumor DNA (ctDNA) for genomic profiling of non-small cell lung cancer (NSCLC): Experience in a large community-based cancer center.

Giselle Alexandra Suero-Abreu

e24026

Circulating tumor DNA analysis for osimertinib resistance Chinese NSCLC patients.

Weiguang Gu

e24061

Circulating tumor DNA as a potential indicator of tumor load during interventional therapy of unresectable hepatocellular carcinoma.

Yong Li

12036

Circulating tumor DNA as biomarker in mutant malignant melanoma.

Jan Braune

12042

Circulating tumor DNA clone analysis to predict disease progression/indicates trastuzumab-resistant mechanism in advanced gastric cancer.

Yan Wang

e24030

Circulation cell-free tumor DNA and extra-tumor heterogeneity in post-mortem examination.

Hayato Koba

e24045

Clinical application of a novel CTC-chip to detect circulating tumor cells (CTCs) in malignant pleural mesothelioma (MPM).

Kazue Yoneda

e24086

Clinical usefulness of liquid biopsy for predictive response biomarkers identification in patients with advanced cancer.

Ivan Gonzalez

e24025

Clinical utility of a novel circulating tumor DNA test in guiding targeted therapy selection.

Tsai Ming Hung

e24082

Combining circulating tumor cells and circulating cancer associated macrophage-like cells for accurately predicting responsiveness of new line therapies in late stage cancers.

Daniel Adams

12032

Copy number variation of genes in cell-free DNA in patients with lung adenocarcinoma.

Denis S. Kutilin

e24060

Correlation between natural killer cell activity and treatment effect in patients with disseminated cancer.

Torben Hansen

12029

Correlation of circulating tumor cell phenotypes based on epithelial-mesenchymal transition with prognosis in first-line chemotherapy of HER2-negative metastatic breast cancer.

Xiuwen Guan

e24039

Correlation of expression of TK1 in plasma-derived exosomes with clinical response to CDK4/6 inhibitors in breast cancer.

Marzia Del Re

12037

Correlation of fatty acid receptor (CD36) positive circulating epithelial tumor cells (CETCs) with aggressiveness of breast cancer disease.

Dorothea Schott

e24032

Correlation of peripheral T cell receptor repertoire with response to neoadjuvant chemotherapy plus trastuzumab in early-stage HER2-positive breast cancer.

Wenna Wang

12035

CTCs enumeration and profile in different cancer types in a group of patients from the United States.

Dimitrios-Athanasios Ntanovasilis

e24033

Detection of androgen receptor expression in circulating tumor cells of metastatic breast cancer patients.

Tanja N. Fehm

e24096

Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: The Circulating Cell-free Genome Atlas (CCGA) study.

Eric A. Klein

12021

Development of diagnostic method for bone and soft tissue sarcomas of various histological subtypes using serum microRNA profiles.

Naofumi Asano

12019

Duvelisib inhibition of chemokines in patients with CLL (DUO study) and iNHL (DYNAMO study).

David T. Weaver

12048

Dynamic change of PD-L1 expression on circulating tumor cells in advanced gastrointestinal tumor patients undergoing PD-1 blockade therapy.

Chunyan Yue

12033

EFIRM liquid biopsy (eLB): Detection of ultra-short circulating tumor DNA (usctDNA) in plasma and saliva of non-small cell lung cancer (NSCLC) patients.

Feng Li

e24062

Exosome liquid biopsies of NSCLC patients for longitudinal monitoring of ALK fusions and resistance mutations.

Kay Brinkmann

e24090

Expansion of oncomine cell-free research panels to enable copy number and gene fusion detection from liquid biopsy samples.

Jian Gu

e24075

Extracellular matrix (ECM) circulating peptide biomarkers as potential predictors of survival in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (mPDA) receiving pegvorhyaluronidase alfa (PEGPH20), nab-paclitaxel (A), and gemcitabine (G).

Song Wang

12030

Extracellular vesicle-derived miRNA profile for patients with pulmonary ground glass nodule.

Jia-Tao Zhang

e24037

Gastric cancer detection using the serum pepsinogen test method in Croatian patients.

Dragan Trivanovic

e24055

High pretreatment neutrophil-to-lymphocyte ratio (NLR) and its reactive increase as better predictors of poor clinical outcomes compared to tumor mutation burden (TMB) in solid tumor patients treated with immune checkpoint inhibitors (ICI).

Vaia Florou

e24109

Hypomethylation and presence of human endogenous retroviruses –h and –k in the extracellular microvescicles of colon cancer patients.

Serena del Bue

e24071

Importance of androgen receptor (AR) to estrogen receptor ratio in breast cancer patients during endocrine therapy determined on circulating epithelial tumor cells (CETCs) in breast cancer patients.

Monika Pizon

e24031

Integration of lymphocyte ratios (LRs) and circulating tumor cells (CTCs) characterization: The interplay between immunity and metastatic breast cancer (MBC).

Lorenzo Gerratana

12039

Landscape of kinase rearrangements (kRE) detected in circulating tumor DNA (ctDNA).

Ben C. Creelan

12041

Liquid biopsies (LB) across treatment of 29 metastatic colorectal cancer (mCRC) patients (pts) to reveal driver mutations and tumor evolution with anti-EGFR therapy: Experience in a GI oncology clinic at Fox Chase Cancer Center.

Pooja Ghatalia

12047

Liquid biopsy to predict benefit from rechallenge with cetuximab (cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to first-line cet+iri: Final results and translational analyses of the CRICKET study by GONO.

Daniele Rossini

12007

Low-coverage, genome-wide sequencing of cell-free DNA developed for noninvasive prenatal testing (NIPT) to enable genomic characterization that can be used to monitor immunotherapy response in cancer patients.

Taylor J. Jensen

e24050

Measuring serum neurofilament light (sNfL) levels to determine correlation with activity of brain metastases (BM) and gliomas (G).

Jason Porter

e24028

Methylomes variation to predict exemestane resistance in advanced breast cancer.

Xiao-Ran Liu

e24029

Molecular analysis of thymidylate synthase in circulating tumor cells as a potential marker of response to therapy in locally advanced rectal cancer.

Virgilio Souza E Silva

e24059

Monitoring advanced non-small cell lung cancer (NSCLC) through plasma genotyping during systemic treatment: KRAS-mutated (m) cohort results.

Laura Bonanno

e24074

Monitoring microsatellite instability (MSI) in circulating tumor DNA by next-generation DNA-seq.

Adam Deng

12025

Monitoring pharmacodynamic response to nucleoside analogs targeting DNMT1 using p16/INK4a re-expression in circulating tumor cells.

Robert J. Kinders

e24069

Multi-centre clinical study of cell-free DNA mutations in benign and malignant lung lesions.

Yuancai Xie

e24036

Mutation count, a potential surrogate for tumor mutation load, of circulating tumor DNA (ctDNA) using targeted panel sequencing correlates with clinical outcomes in late stage lung adenocarcinoma and small cell lung cancer.

Stephanie Yaung

12045

Mutation tracking of circulating tumor DNA during neoadjuvant period predicts relapse in stage II-III breast cancer patients.

Po-Han Lin

e24101

Neutrophil-to-lymphocyte ratio (NLR) conversion during checkpoint inhibitors therapy as a early prognostic factor.

Jefferson Rios Pimenta

e24038

NLR as a prognostic factor in solid tumors.

Yifei Zhang

e24057

NRG Oncology/NSABP B-31: Stromal tumor infiltrating lymphocytes (sTILs) and outcomes in early-stage HER2-positive breast cancer (BC).

Rim S. Kim

12010

PD-L1 expression on circulating tumor cells in patients with hepatocellular carcinoma.

Hee Yeon Kim

e24095

PD-L1+CD4+ T cells and soluble PD-L1 as prognostic factors to anti-PD-1 immunotherapy in advanced non small cell lung cancer patients.

EleniKyriaki Vetsika

e24091

Predictive tools for bevacizumab therapy in patients with aggressive HER 2-negative metastatic breast cancer: 2-years results from an observational study.

Encarnación González Flores

12043

Prognostic value of Mesenchymal Circulating Tumour Cells: Dynamic monitoring in patients with colorectal cancer.

Bin Xiong

e24052

Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results.

Vamsidhar Velcheti

12001

Prospective comparison of invasive circulating tumor cells (iCTCs) vs PSA and mpfs in prostate cancer (PC) treated with SM-88.

Wen-Tien Chen

e24072

Prospective serial sequencing of CTC/cfDNA and NK cell activity in patients undergoing multimodality treatment for triple negative breast cancer.

Hanna Irie

e24108

Prospective study on the role of cytidine deaminase activity in lung cancer patients treated with gemcitabine-platinum-based chemotherapy.

Elisa Giovannetti

e24078

Quantification of circulating tumor cells as a biomarker for surveillance in oligometastatic patients after definitive radiation therapy.

Daniel Paul Lindsay

e24106

Re-visiting EGFR amplification as a target for anti-EGFR therapy: Analysis of cell-free circulating tumor DNA in patients with diverse cancers.

Shumei Kato

12028

Role of circulating tumor cells by rare cell enumeration system in predicting response of non-small cell lung cancers to therapy.

Midhun Malla

e24058

Role of serum thymidine kinase-1 (TK1) activity in patients (pts) with hormone receptor positive (HR+) advanced breast cancer (ABC) treated with endocrine therapy (ET) in the EFECT trial.

Luca Malorni

12031

Specificity in endogenous intoxication development in patients with different stages of gynecologic cancer.

Polina S. Kachesova

e24093

Study of non-small cell lung cancer using ultra-high-performance liquid chromatography-mass spectrometry.

Kai Zhang

e24085

Surveying the genomic landscape of somatic short insertions and deletions in over 2,000 cancer patients.

Shifu Chen

e24083

The prognostic and predictive value of AR-V7 quantification in mCRPC.

Adam Sharp

12026

The prognostic impact of plasma methylated HOXA9 in patients with advanced non-small cell lung cancer.

Sara Witting Christensen

e24063

The relationship between IL-33 and monocyte-macrophages in esophageal squamous cell carcinoma.

Shijie MAI

e24056

The significance of monitoring KRAS, human epidermal growth factor receptor 2, and vascular endothelial growth factor signals in the blood of colorectal cancer patients during treatment.

Koichi Suzuki

e24053

Theoretical model and clinical validation of blood tumor mutation burden (bTMB) detection for cancer immunotherapy.

Jianchun Duan

12034

Therapeutic response monitoring using digital PCR for patient-specific circulating tumor DNA identified by an esophageal squamous cell carcinoma-specific sequencing panel.

Takeshi Iwaya

e24089

Use of cell-free DNA for management of breast and lung cancer by academic and community providers.

Roby Antony Thomas

12046